[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-tract-infections-in-children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-tract-infections-in-children":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,65,90,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100383878","pharmacokinetics-pharmacodynamics-and-safety-profile-of-understudied-drugs-administered-to-children-per-standard-of-care-pops-100383878",false,"NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","POPS or POP02","Inclusion Criteria:\n\n1. Participant is \\\u003C 21 years of age\n2. Parent\u002F Legal Guardian\u002F Adult Participant can understand the consent process and is willing to provide informed consent\u002FHIPAA:\n3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment\n\nExclusion Criteria:\n\n1. Participant has a known pregnancy\n\n   Below exclusion criteria apply only to:\n\n   Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)\n2. Has had intermittent dialysis within previous 24 hours\n3. Has had a kidney transplant within previous 30 days\n4. Has had a liver transplant within previous 1 year\n5. Has had a stem cell transplant within previous 1 year\n6. Has had therapeutic hypothermia within previous 24 hours\n7. Has had plasmapheresis within the previous 24 hours\n8. Has a Ventricular Assist Device\n9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study",true,"ALL","0 Years","20 Years",{"count":22,"type":23},5000,"ESTIMATED","OBSERVATIONAL","The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome","RECRUITING","2026-03-31",{"date":55,"type":56},"2026-04-06","ACTUAL",{"date":58,"type":56},"2020-03-05",{"date":60,"type":23},"2027-07",{"name":62,"class":63},"Duke University","OTHER",51,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":18,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100349136","research-of-the-consequences-on-the-digestive-tract-following-the-proposed-treatments-for-a-urinary-infection-in-children-100349136","NCT03825874","Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children","Comparison of the Impact on Digestive Portage of Broad Spectrum Beta-Lactamase-Producing Enterobacteriaceae (E-ESBLs) of Proposed Treatments in Outbreaks of Childhood Urinary Tract Infection","MIKA","Inclusion Criteria:\n\n* Infant and child (age ≥ 3 months and \\\u003C3 years)\n* Patient treated for febrile urinary tract infection as monotherapy with amikacin IV, ceftriaxone (IV or IM) or cefixime PO \\*\n* Whose parents read and understood the newsletter and whose express consent was collected\n* Patient affiliated to a social security scheme (Social Security or Universal Medical Coverage)\n\nExclusion Criteria:\n\n* Child treated with more than one antibiotic (eg treatment with dual therapy ceftriaxone \u002F cefotaxime and aminoglycoside)\n* Antibiotherapy in progress or discontinued in the previous 7 days\n* Hospitalized child\n* Refusal of one of the parents","3 Months","3 Years",{"count":76,"type":23},200,"The emergence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (E-ESBL) is a major public health problem. It leads more frequent prescription of penems with the risk of emergence and spread of strains producing carbapenemases, which may be resistant to all known antibiotics. A policy of savings of penems is desirable. Among the alternatives to penems, amikacin is in the foreground. It remains active on the majority of E-ESBL strains. Some risk factors for E-ESBL emergence are known: recent antibiotic therapy (particularly quinolones and cephalosporins third generation), previous hospitalization or residence in a high endemic country.\n\nIn pediatrics, E-ESBLs are primarily responsible for urinary tract infection. In France, E-ESBLs represent about 10% of the strains responsible for urinary tract infections. The Pathology Group Pediatric Infectious (GPIP) of the French Society of Pediatrics (SFP) and the Society of Infectious Pathology French Language (SPILF) have proposed different therapeutic options to treat febrile UTIs in children: amikacin intravenous; intravenous (IV) ceftriaxone or intramuscular (IM); or cefixime per-os (PO).\n\nThe objective of this study is to compare the emergence of E-ESBLs in stools of children after febrile UTIs treatment with amikacin IV versus ceftriaxone or cefixime.",[79,29],"Urinary Tract Infections","2025-08-26",{"date":82,"type":56},"2025-08-27",{"date":84,"type":56},"2019-01-19",{"date":86,"type":23},"2026-07",{"name":88,"class":63},"Centre Hospitalier Intercommunal Creteil",20,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":18,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":95,"conditions":101,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100564159","urinary-tract-infection-in-assiut-university-children-hospital-100564159","NCT06625554","Urinary Tract Infection In Assiut University Children Hospital","Antibiotic Sensitivity Pattern and Demographic Characteristics of Urinary Tract Infection In Assiut University Children Hospital","Inclusion Criteria:\n\n* 1-Children over 1 month and less than 18 year of age. 2-Diagnosed cases of Urinary Tract Infection. 3-who accepted to participate in the study.\n\nExclusion Criteria:\n\n* 1-neonates and patients more than 18 year. 2-children with chronic kidney diseases. 3-who refused to participate in our study.","1 Month","17 Years",{"count":100,"type":23},75,[29],"NOT_YET_RECRUITING","2024-10-01",{"date":105,"type":56},"2024-10-03",{"date":107,"type":23},"2025-01-01",{"date":109,"type":23},"2025-12-31",{"name":111,"class":63},"Assiut University",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":18,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":5},"100502205","oral-antibiotics-alone-in-children-aged-4-weeks-to-2-months-with-a-urinary-tract-infection-100502205","NCT05819229","Oral Antibiotics Alone in Children Aged 4 Weeks to 2 Months With a Urinary Tract Infection","Oral Antibiotics Alone in Children Aged 4 Weeks to 2 Months With a Suspected or Confirmed Uncomplicated Urinary Tract Infection. A Single-arm Multicenter Prospective Observational Study.","INCLUSION CRITERIA:\n\n1. Clinical suspicion of urinary tract infection irrespective of the presence of fever.\n2. Clinically stable (i.e., not respiratory or circulatory affected, septic, or meningeal).\n3. 4 weeks to 2 months of age (corrected age, if premature).\n\nAll children who do not receive any empirical antibiotic therapy but have a positive urine culture can be included if the clinical suspicion of urinary tract infection persists.\n\nA positive urine culture is defined as:\n\n* Suprapubic bladder aspiration: any growth of bacteria.\n* Sterile intermittent catheterization: monoculture with ≥10\\^3 colony forming units per milliliter (cfu\u002Fml).\n* Midstream urine x 2: monoculture with the same bacteria in both tests with ≥10\\^4 cfu\u002Fml.\n* Midstream urine x 2: monoculture with the same bacteria in both tests with ≥10\\^5 cfu\u002Fml in one test and 10\\^3 cfu\u002Fml in another test.\n\nEXCLUSION CRITERIA:\n\n1. Non-Danish civil registration number.\n2. High-risk medical history.\n\n   1. Previous urinary tract infection.\n   2. Prophylactic antibiotic treatment.\n   3. Known urogenital abnormality (i.e., hydronephrosis (pyelectasis ≥10 mm or\u002Fand caliectasis ≥5 mm); hydroureter; vesicoureteral reflux; multicystic dysplasia; renal dysplasia; renal hypoplasia; renal agenesis; duplex kidney; ectopic placed kidneys; polycystic kidney disease; neurogenic bladder dysfunction; and hypospadias).\n   4. Previous hospitalization needing antibiotic therapy.\n3. Markedly elevated c-reactive protein indicating bacteremia.\n4. Elevated creatinine.\n5. Oral therapy is not possible (e.g., frequent vomiting or excessive regurgitation).","4 Weeks","2 Months",{"count":122,"type":23},125,"The goal of this prospective study is to investigate whether oral antibiotic therapy alone is feasible and safe in clinically stable children aged 4 weeks to 2 months without any past high-risk medical history with a suspected or confirmed urinary tract infection.",[29],[126,127,128],"Antibiotic therapy","Urinary tract infection","Children","2024-07-05",{"date":131,"type":56},"2024-07-08",{"date":133,"type":56},"2023-02-27",{"date":135,"type":23},"2025-05-01",{"name":137,"class":63},"Rigshospitalet, Denmark"]